Program for all days

• High Level Summary of the Two Previous Webinars
  AdeeraLevin Speaker alevin@providencehealth.bc.caCanada
• Designing Trials for Inclusivity and Generalizability
  Andrea Viecelli Speaker andrea.viecelli@usz.chSwitzerland
• Trials Without Borders
  RathikaKrishnasamy Speaker Rathika.Krishnasamy@health.qld.gov.auAustralia
• Use of Novel Tools in Kidney Research
  Pedro HenriqueFranca Gois Speaker pedro.francagois@health.nsw.gov.auAustralia
• Q&A Session

• Practical Aspects of Implementation Science; Hands-on Studies
  Tae WonYi Speaker taewon.yi@gmail.comCanada
• Value of Implementation Science
  RukshanaShroff Speaker Rukshana.Shroff@gosh.nhs.ukUnited Kingdom
• Implementation Science in Digital Health: Clinical Trials Using Mobile Applications for Patient Interventions
  YusukeSakaguchi Speaker sakaguchi@kid.med.osaka-u.ac.jpJapan
• Take Home Messages
  MegJardine Speaker meg.jardine@sydney.edu.auAustralia

• REMODEL Trial Overview: Framework and Key Outcomes
  PetterBjornstad Speaker pettermb@uw.eduUnited States
• Semaglutide Improves Kidney Outcomes Regardless Of SGLT2i Use In People With Chronic Kidney Disease And Type 2 Diabetes: Post-hoc Analysis The Remodel Trial
  DavidCherney Speaker david.cherney@uhn.on.caCanada
• Aldosterone Blockade for Health Improvement Evaluation in End-stage Renal Disease Trial
  (ACHIEVE)
  MichaelWalsh Speaker lastwalsh1975@gmail.comCanada
• B-cell Targeted Therapy for Idiopathic Nephrotic Syndrome: Results of the Phase III Global Multicenter Inshore Trial Evaluating Efficacy and Safety of Obinutuzumab vs Mycophenolate Mofetil
  JulienHogan Speaker julien.hogan2@aphp.frFrance
• Q&A Session

• RESOLVE Trial: Sodium Concentration in Dialysis Populations — a Global Cluster Randomized Study
  MegJardine Speaker meg.jardine@sydney.edu.auAustralia
• Q&A
• Key Aspects of the VOICE Clinical Trial on Anemia in Dialysis Patients
  ShuchiAnand Speaker sanand2@stanford.eduUnited States
• Q&A
• TEACH-PD Cluster Randomized Controlled Trial: Targeted Education ApproaCH to improve Peritoneal Dialysis Outcomes
  JosephineChow Speaker Josephine.Chow@health.nsw.gov.auAustralia
• Q&A
• The Renal Life Cycle: Development, Maturity, and Decline
  HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands
• Q&A
• Randomized Embedded Adaptive Platform Clinical Trial in South Asian Kidney Biopsy-proven Primary Glomerular Diseases: Multi-center, Multi-arm and Multi-stage- the Story So Far
  Joint Presentation
  Selvin Sundar RajMani Speaker selvinsr@gmail.comIndia

  SuceenaAlexander Speaker suceena@gmail.comIndia
• Q&A
• ASPIRE Trial: Aspirin Use in Dialysis Patients in China
  XueqingYu Speaker yuxueqing@gdph.org.cnChina
• Q&A

• Efficacy and Safety Results of Atrasentan in Patients With IgA Nephropathy on Sodium‚ äìglucose Co-transporter 2 Inhibitors: Phase II, Randomized, Placebo-controlled, Crossover Trial (Assist)
  HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands
• Efficacy and Safety of a Targeted-release Formulation of Budesonide (HR19042 Capsules) in Patients With Primary IgA Nephropathy: A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2/3 Trial
  XiaobingYang Speaker yxb7829@163.comChina
• Efficacy and Safety of Iptacopan in Patients With IgA Nephropathy (IgAN): Final 24-month Results From the Phase III APPLAUSE-IgAN Study
  VladoPerkovic Speaker vlado.perkovic@unsw.edu.auAustralia
• Q&A

• Advancing the Next Wave of Therapies in Chronic Kidney Disease
  DustinLittle Speaker dustin.little@astrazeneca.comUnited States
• Effects of Finerenone on Biomarkers: Mechanistic Insights From Proteomic Analyses in Clinical Trials
  MarioBerger Speaker mario.berger@bayer.comGermany
• Future Directions in CRM Care: Advancing Research and Therapeutic Innovation
  AntonioGarreta Rufas Speaker antonio.garreta_rufas@boehringer-ingelheim.comGermany
• Innovative Strategies for Clinical Trial Design in IgAN
  LokeshShah Speaker lokesh.shah@otsuka-us.comUnited States
• Improving Outcomes in Complement-mediated Kidney Diseases
  Marianne Silkjær Nielsen Speaker Msn@compcure.orgSwitzerland
• Advancing Mechanistic Trials through Industry–Academia Collaboration: Insights from the REMODEL Trial
  ManuelMayrdorfer Speaker mumf@novonordisk.comDenmark
• Why? When? How? How to Maximize Patient Outcomes From the Start of Dialysis
  PeterRutherford Speaker peter.rutherford@vantive.comSwitzerland

• Kidney International in Focus: Annual Highlights
  PierreRonco Speaker pierreronco@yahoo.frFrance
• ISN-KI Fellows: Showcasing Excellence, Part 1 — Pediatrics
  GabrielCara-Fuentes Speaker Gabriel.CaraFuentes@NationwideChildrens.orgUnited States
• ISN-KI Fellows: Showcasing Excellence, Part 2 — Clinical Nephrology
  SaharKoubar Speaker skoubar@umn.eduUnited States
• ISN-KI Fellows: Showcasing Excellence Part 3 — Epidemiology & Clinical Trials
  DavidTunnicliffe Speaker david.tunnicliffe@sydney.edu.auAustralia
• ISN-KI Fellows: Showcasing Excellence, Part 4 — Basic and Translational Science
  NahidTabibzadeh Speaker nahid.tabibzadeh@inserm.frFrance
• Kidney International Reports in Focus: Annual Highlights
  JaiRadhakrishnan Speaker jr55@cumc.columbia.eduUnited States
• Kidney International Reports in Focus: Annual Highlights
  SumitMohan Speaker mohan.sumit@gmail.comUnited States
• Kidney International Reports in Focus: Annual Highlights
  SumitMohan Speaker mohan.sumit@gmail.comUnited States
• Celebrating Excellence: Best Reviewer Awards Presentation
  BradRovin Speaker rovin.1@osu.eduUnited States
• Presentation of Basic Science Awards (Early Career Researcher Awards)
  BERNHARDDUMOULIN Speaker bernhard.dumoulin@gmail.comUnited States
• Presentation of Clinical Science Awards (Early Career Researcher Awards)
  Louis-CharlesDesbiens Speaker louischarles.desbiens@gmail.comCanada
• ISN-KI Fellows: Where Are They Now?
  GermaineWong Speaker germaine.wong@health.nsw.gov.auAustralia

• Effect of a 12-week Intradialytic Cycling Intervention on Hemodialysis-induced Myocardial Stunning: A Multi-centre Randomized Controlled Trial
  ClaraBohm Speaker cbohm@sogh.mb.caCanada
• Effect of Finerenone on Circulating Biomarkers: A CONFIDENCE Analysis
  MarioBerger Speaker mario.berger@bayer.comGermany
• Effect of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-creatinine Ratio by Age and Sex in the CONFIDENCE Trial
  RajivAgarwal Speaker ragarwal@iu.eduUnited States
• Estimated Glomerular Filtration Rate, Systolic Blood Pressure, and Urinary Albumin-to-creatinine Ratio — Unravelling the Interplay in Combination: Findings From the CONFIDENCE Trial
  RajivAgarwal Speaker ragarwal@iu.eduUnited States
• Lowering-Hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients: A Prospective, Multicenter, Double Blind Randomized Controlled Trial
  Naya Huang Speaker huangnaya@163.comChina

• Building Clinical Trial Awareness in the Kidney Community
  Andrea Viecelli Speaker andrea.viecelli@usz.chSwitzerland
• ISN TrialWatch: Bringing the Latest Evidence to the Kidney Community
  MeganBorkum Speaker mborkum@gmail.comCanada
• The ISN Guide for Everyone: Demystifying Clinical Research
  AdeeraLevin Speaker alevin@providencehealth.bc.caCanada